Learning from Failure
Cardiovascular toxicity often hinders success – are companies picking the wrong compounds?
William Aryitey |
Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.)
When it comes to drug safety failure, toxicity – especially to the cardiovascular system – is a major stumbling block. In an effort to learn from past failures and help improve success rates, ApconiX and PhysioStim have teamed up to create a European center of excellence for preclinical cardiovascular safety evaluation. The companies hope to provide high-throughput screening to help pharma companies decide whether their compound is on the right track to pass safety tests. Here, we speak with a spokesperson from ApconiX to
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine